Integrated Laboratory Evaluation of Rift Valley Fever Virus Antibodies Using the Competitive ELISA and Virus Neutralization Test
Pathogens · 2026
DOI: 10.3390/pathogens15030264 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Pathogens, 2026. Verfasst von Ommer M Dafalla und 10 weiteren Autor:innen. Beteiligte Einrichtung: The National Center for the Prevention & Control of Plant Pests & Animal Diseases (Weqaa), Operation Sector, General Department of Laboratories-Jazan…. Hauptthemen laut MEDLINE: Rift Valley fever virus, Neutralization Tests, Antibodies, Viral, Rift Valley Fever. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Rift Valley fever virus (RVFV) is a significant mosquito-borne zoonotic virus with high public health and veterinary importance in Africa and the Middle East. Reliable diagnostic assays for detecting antibodies and assessing their functional neutralizing capacity are essential for surveillance programs, vaccine monitoring, and outbreak preparedness.
Objective
This study evaluates and compares the analytical performance of a competitive enzyme-linked immunosorbent assay (cELISA) and a virus neutralization test (VNT) for detecting RVFV antibodies in vaccinated sheep sera, establishing an integrated laboratory workflow for virus titration, serological detection, and functional neutralization.
Methods
Twenty serum samples were collected from sheep pre-vaccination and one month post-vaccination with Smithburn live attenuated RVFV vaccine. Sera were tested using a commercial multispecies RVFV competitive ELISA to detect antibodies specific to the viral nucleocapsid protein. Viral titration was conducted in Vero cells, and 50% tissue culture infective dose (TCID50/0.1 mL) was calculated using the Reed and Muench method. VNT was performed at 24, 48, 72, and 96 h after infection with different viral doses (102 to 105 TCID50/0.1 mL), and the neutralizing ability of serial serum dilutions (1:2 to 1:1024) was tested. Compared with the control, protection was determined by cytopathic effect (CPE) inhibition.
Results
ELISA revealed robust antibody signals up to a 1:32 dilution, with signal-to-noise (S/N) < 40%, whereas for higher dilutions, antibody detection became inconclusive or negative. Virus titration was performed to verify a stock concentration of 106.5 TCID50/0.1 mL. The VNT exhibited time- and dose-dependent kinetics; high protection rates (≥97) were observed at 1:2–1:8 dilutions against 102–103 TCID50/0.1 mL challenge doses; however, neutralizing efficacy decreased significantly at higher viral loads and higher serum dilutions. While cELISA and VNT results correlated strongly at low serum dilutions, the cELISA showed decreased sensitivity at dilutions ≥ 1:64, where the VNT remained capable of detecting functional neutralizing activity. Conclusions/Discussion: The results demonstrate that while both assays correlate well at high antibody concentrations, they diverge at lower concentrations. This discrepancy highlights the functional difference between binding antibodies (N-protein) and neutralizing antibodies (Gn/Gc glycoproteins). Consequently, the cELISA is ideal for rapid screening, whereas the VNT is indispensable for confirming functional immunity. Integrating both assays provides a more accurate immunological profile for RVFV surveillance and vaccine evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The National Center for the Prevention & Control of Plant Pests & Animal Diseases (Weqaa), Operation Sector, General Department of Laboratories-Jazan Laboratory, Jizan 82224 , Saudi Arabia.
- The National Center for the Prevention & Control of Plant Pests & Animal Diseases (Weqaa), Operation Sector, General Department of Laboratories, Riyadh, 11461, Saudi Arabia.
ORCID-Profile: Ommer M Dafalla, Mohammed O Hussien, Tellal B Ageep
Zitieren
APA
Dafalla, O. M., Alashor, A. A., Hussien, M. O., Noureldin, E. M., Ageep, T. B., Najmi, M. A., Mohamed, M. S., Hakami, A. A., Alrashedi, S. A., Bushlaibi, F. A., & Abukhalil, F. N. (2026). Integrated Laboratory Evaluation of Rift Valley Fever Virus Antibodies Using the Competitive ELISA and Virus Neutralization Test. Pathogens. https://doi.org/10.3390/pathogens15030264
Vancouver
Dafalla OM, Alashor AA, Hussien MO, Noureldin EM, Ageep TB, Najmi MA, et al. Integrated Laboratory Evaluation of Rift Valley Fever Virus Antibodies Using the Competitive ELISA and Virus Neutralization Test. Pathogens. 2026. doi:10.3390/pathogens15030264
BibTeX
@article{Dafalla2026,
author = {Dafalla, Ommer M and Alashor, Abdullah A and Hussien, Mohammed O and Noureldin, Elsiddig M and Ageep, Tellal B and Najmi, Mohammed A and Mohamed, Mohamed S and Hakami, Ali A and Alrashedi, Saleh A and Bushlaibi, Fisal A and Abukhalil, Fahad N},
title = {Integrated Laboratory Evaluation of Rift Valley Fever Virus Antibodies Using the Competitive ELISA and Virus Neutralization Test},
journal = {Pathogens},
year = {2026},
doi = {10.3390/pathogens15030264}
}
EUVIMED